Study summary · research use only
Latest on Anabolic Agents for Osteoporosis Treatment
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This narrative review (species not specified) discusses anabolic bone therapeutics used in osteoporosis management, particularly in patients at high risk of fragility fracture, including the PTH-related analogues teriparatide and abaloparatide, and the anti-sclerostin agent romosozumab, the latter currently approved only in female patients. The review describes these drugs' association with reduced fragility fractures as widely reported in prior studies, and describes potential serious side effects, including malignancy risk associated with teriparatide and cardiovascular events associated with romosozumab, as having been reassessed downward over time. The authors note further data are needed on their use in glucocorticoid-induced osteoporosis and fracture healing.
Abstract
In the last decades, novel therapeutics with anabolic bone properties have been developed and are currently used in the management of osteoporosis particularly in patients with high-risk of fragility fractures. These drugs include PTH-Related Analogues, teriparatide and abaloparatide, and the anti-sclerostin agent romosozumab, this latter drug currently approved only in female patients. Their efficacies in preventing fragility fractures are widely demonstrated and their potential serious side effects were progressively downgraded, including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further data are warranted about their efficacy in glucocorticoids-induces osteoporosis and fracture healings.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.